affitope pd03a
Vaccineexperimental
Clinical trial activity
2 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2014 (NCT02267434)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Alpha-synucleinImmunity, active
SNCA immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- affitope pd03a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02270489 | Phase 1 | Dec 11, 2014 | Affiris AG, Forschungszentrum Jülich, Institut National de la Santé Et de la Recherche Médicale, France, University of Bordeaux, University of Toulouse |
| NCT02267434 | Phase 1 | Dec 1, 2014 | Affiris AG, Forschungszentrum Jülich, Medical University Innsbruck, Prosenex Ambulatorium BetriebsgmbH |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Affiris AG | For profit | 2 | 2 | 1 | 2014 |
| Forschungszentrum Jülich | Academic/Hospital | 2 | 0 | 1 | 2014 |
| Institut National de la Santé Et de la Recherche Médicale, France | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Medical University Innsbruck | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Prosenex Ambulatorium BetriebsgmbH | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Bordeaux | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Toulouse | Academic/Hospital | 1 | 0 | 1 | 2014 |
7 organizations
Page 1 / 1